MICA and recovery from hepatitis C virus and hepatitis B virus infections

P. S. Karacki; X. Gao; C. L. Thio; D. L. Thomas; J. J. Goedert; D. Vlahov; R. A. Kaslow; S. Strathdee; M. W. Hilgartner; S. J. O'Brien; M. Carrington

doi:10.1038/sj.gene.6364065

MICA and recovery from hepatitis C virus and hepatitis B virus infections

P. S. Karacki, X. Gao, C. L. Thio, D. L. Thomas, J. J. Goedert, D. Vlahov, R. A. Kaslow, S. Strathdee, M. W. Hilgartner, S. J. O'Brien, M. Carrington

School of Medicine

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

The polymorphic MHC class I chain-related A (MICA) gene encodes a ligand that has different binding affinities for the NKG2D activating receptor of CD8+ T cells and natural killer (NK) cells. We hypothesized that MICA heterogeneity would affect recovery from hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. To test the hypothesis, we initially typed known MICA polymorphisms for 228 persons who cleared HCV infection and 442 persons with persistent hepatitis C matched on other factors affecting viral persistence. Although MICA*015 was detected more than two-fold more often in persons with viral clearance (odds ratio 0.36, 95% confidence interval=0.19, 0.80), it occurred in fewer than 5% of the study population. In a similar analysis of 442 persons with chronic hepatitis B and 768 matched controls who recovered, MICA*015 was detected in 2.0% of persons with chronic hepatitis B and only 0.9% of controls. No significant associations were detected with other MICA polymorphisms. While further investigation may reveal a structural basis of the MICA*015 associations, these data provide little support for the hypothesis that differential distribution of MICA alleles substantially affects recovery from HCV and HBV infections.

Original language	English (US)
Pages (from-to)	261-266
Number of pages	6
Journal	Genes and immunity
Volume	5
Issue number	4
DOIs	https://doi.org/10.1038/sj.gene.6364065
State	Published - Jun 2004

Keywords

Genetics
HBV
HCV
MICA
Pathogenesis
Viral persistence

ASJC Scopus subject areas

Immunology
Genetics
Genetics(clinical)

Access to Document

10.1038/sj.gene.6364065

Cite this

@article{4ac2d6ffbb73442fa2c7d10543d12027,

title = "MICA and recovery from hepatitis C virus and hepatitis B virus infections",

abstract = "The polymorphic MHC class I chain-related A (MICA) gene encodes a ligand that has different binding affinities for the NKG2D activating receptor of CD8+ T cells and natural killer (NK) cells. We hypothesized that MICA heterogeneity would affect recovery from hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. To test the hypothesis, we initially typed known MICA polymorphisms for 228 persons who cleared HCV infection and 442 persons with persistent hepatitis C matched on other factors affecting viral persistence. Although MICA*015 was detected more than two-fold more often in persons with viral clearance (odds ratio 0.36, 95% confidence interval=0.19, 0.80), it occurred in fewer than 5% of the study population. In a similar analysis of 442 persons with chronic hepatitis B and 768 matched controls who recovered, MICA*015 was detected in 2.0% of persons with chronic hepatitis B and only 0.9% of controls. No significant associations were detected with other MICA polymorphisms. While further investigation may reveal a structural basis of the MICA*015 associations, these data provide little support for the hypothesis that differential distribution of MICA alleles substantially affects recovery from HCV and HBV infections.",

keywords = "Genetics, HBV, HCV, MICA, Pathogenesis, Viral persistence",

author = "Karacki, {P. S.} and X. Gao and Thio, {C. L.} and Thomas, {D. L.} and Goedert, {J. J.} and D. Vlahov and Kaslow, {R. A.} and S. Strathdee and Hilgartner, {M. W.} and O'Brien, {S. J.} and M. Carrington",

note = "Funding Information: This work was supported by NIH Grants DA00441, DA04334, and DA13324. CT was additionally supported, in part, by the Investigators in the Pathogenesis of Infectious Diseases Award from the Burroughs Wellcome Fund. The Multicenter AIDS Cohort Study (MACS) is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute: UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041. MHCS is supported by National Cancer Institute contract N01-CP-33002 with Research Triangle Institute. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. NO1-CO-56000. The publisher or recipient acknowledges rights of the US Government to retain a nonexclusive, royalty-free license in and to any copyright covering the article.",

year = "2004",

month = jun,

doi = "10.1038/sj.gene.6364065",

language = "English (US)",

volume = "5",

pages = "261--266",

journal = "Genes and immunity",

issn = "1466-4879",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - MICA and recovery from hepatitis C virus and hepatitis B virus infections

AU - Karacki, P. S.

AU - Gao, X.

AU - Thio, C. L.

AU - Thomas, D. L.

AU - Goedert, J. J.

AU - Vlahov, D.

AU - Kaslow, R. A.

AU - Strathdee, S.

AU - Hilgartner, M. W.

AU - O'Brien, S. J.

AU - Carrington, M.

N1 - Funding Information: This work was supported by NIH Grants DA00441, DA04334, and DA13324. CT was additionally supported, in part, by the Investigators in the Pathogenesis of Infectious Diseases Award from the Burroughs Wellcome Fund. The Multicenter AIDS Cohort Study (MACS) is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute: UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041. MHCS is supported by National Cancer Institute contract N01-CP-33002 with Research Triangle Institute. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. NO1-CO-56000. The publisher or recipient acknowledges rights of the US Government to retain a nonexclusive, royalty-free license in and to any copyright covering the article.

PY - 2004/6

Y1 - 2004/6

N2 - The polymorphic MHC class I chain-related A (MICA) gene encodes a ligand that has different binding affinities for the NKG2D activating receptor of CD8+ T cells and natural killer (NK) cells. We hypothesized that MICA heterogeneity would affect recovery from hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. To test the hypothesis, we initially typed known MICA polymorphisms for 228 persons who cleared HCV infection and 442 persons with persistent hepatitis C matched on other factors affecting viral persistence. Although MICA*015 was detected more than two-fold more often in persons with viral clearance (odds ratio 0.36, 95% confidence interval=0.19, 0.80), it occurred in fewer than 5% of the study population. In a similar analysis of 442 persons with chronic hepatitis B and 768 matched controls who recovered, MICA*015 was detected in 2.0% of persons with chronic hepatitis B and only 0.9% of controls. No significant associations were detected with other MICA polymorphisms. While further investigation may reveal a structural basis of the MICA*015 associations, these data provide little support for the hypothesis that differential distribution of MICA alleles substantially affects recovery from HCV and HBV infections.

AB - The polymorphic MHC class I chain-related A (MICA) gene encodes a ligand that has different binding affinities for the NKG2D activating receptor of CD8+ T cells and natural killer (NK) cells. We hypothesized that MICA heterogeneity would affect recovery from hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. To test the hypothesis, we initially typed known MICA polymorphisms for 228 persons who cleared HCV infection and 442 persons with persistent hepatitis C matched on other factors affecting viral persistence. Although MICA*015 was detected more than two-fold more often in persons with viral clearance (odds ratio 0.36, 95% confidence interval=0.19, 0.80), it occurred in fewer than 5% of the study population. In a similar analysis of 442 persons with chronic hepatitis B and 768 matched controls who recovered, MICA*015 was detected in 2.0% of persons with chronic hepatitis B and only 0.9% of controls. No significant associations were detected with other MICA polymorphisms. While further investigation may reveal a structural basis of the MICA*015 associations, these data provide little support for the hypothesis that differential distribution of MICA alleles substantially affects recovery from HCV and HBV infections.

KW - Genetics

KW - HBV

KW - HCV

KW - MICA

KW - Pathogenesis

KW - Viral persistence

UR - http://www.scopus.com/inward/record.url?scp=3242663431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242663431&partnerID=8YFLogxK

U2 - 10.1038/sj.gene.6364065

DO - 10.1038/sj.gene.6364065

M3 - Article

C2 - 15029237

AN - SCOPUS:3242663431

SN - 1466-4879

VL - 5

SP - 261

EP - 266

JO - Genes and immunity

JF - Genes and immunity

IS - 4

ER -

MICA and recovery from hepatitis C virus and hepatitis B virus infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this